FDA approves Intercept's Ocaliva for PBC

FDA granted accelerated approval to Ocaliva obeticholic acid from Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) to treat primary biliary cholangitis in combination with ursodeoxycholic

Read the full 229 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE